MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-07-2026
Gilead Sciences ROCE Ratio 2011-2026 | GILD
Annual ROCE Ratio Gilead Sciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 44.14 | 8.6 | 33.31 | 34.51 | 47.09 | 22.34 | 8.27 | 15.45 | 24.08 | 36.92 | 52.91 | 52.81 | 27.98 | 23.63 | 25.63 | 67.57 | 55.43 | 62.69 | 57.68 | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 67.57 | 8.27 | 36.9 |
Quarterly ROCE Ratio Gilead Sciences
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | 2010-Q1 | 2009-Q3 | 2009-Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 50.69 | 44.52 | 43.61 | 6.27 | -5.4 | 6.39 | 9.46 | 3.07 | 27.83 | 41.3 | 39.55 | 32.64 | 24.5 | 42.39 | 40.32 | 45.52 | 44.53 | 55.52 | 21.24 | 23.04 | 7.8 | 1.26 | 1.06 | 27.38 | 14.18 | 26.44 | 43.64 | 42.92 | 32.99 | 51.64 | 60.19 | 67.95 | 57.89 | 81.18 | 86.56 | 90.37 | 71.94 | 102.08 | 109.09 | 114.04 | 89.41 | 111.97 | 110.44 | 99.87 | 70.89 | 80.98 | 68.57 | 48.99 | 29.26 | 40.48 | 41.76 | 40.2 | 31.18 | 46.08 | 49.95 | 51.96 | 43.37 | 60.52 | 60.76 | 61.48 | 63.94 | 61.45 | 15.82 | 15.84 | 14.66 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 114.04 | -5.4 | 47.65 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
-299.89 | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
2.89 | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
-27.78 | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
64924.32 | - | -10.17 % | $ 12.2 K |  USA |
 |
Deciphera Pharmaceuticals
DCPH
|
-60.12 | - | - | $ 2.18 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
17.36 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
-49.48 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
3539.01 | - | -13.47 % | $ 169 M | France |
 |
Compugen Ltd.
CGEN
|
23.38 | $ 2.17 | -2.48 % | $ 203 M |  Israel |
 |
AstraZeneca PLC
AZN
|
16.47 | - | - | $ 96.9 B |  Britain |
 |
BioNTech SE
BNTX
|
-7.08 | $ 88.82 | -0.86 % | $ 21.5 B | Germany |
 |
Coherus BioSciences
CHRS
|
-296.87 | $ 1.52 | -3.81 % | $ 178 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-61.36 | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
-368.0 | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
-41.41 | - | 0.74 % | $ 768 M | Israel |
 |
Abcam plc
ABCM
|
-1.18 | - | - | $ 4.9 B | Britain |
 |
CRISPR Therapeutics AG
CRSP
|
-34.58 | $ 53.21 | -6.57 % | $ 4.78 B |  Schweiz |
 |
Galera Therapeutics
GRTX
|
-63.97 | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
-71.74 | - | -18.52 % | $ 27.3 M | Britain |
 |
Affimed N.V.
AFMD
|
-149.7 | - | -34.95 % | $ 21.5 M | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
15.18 | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
-88.5 | - | - | $ 231 M | USA |
 |
Celyad Oncology SA
CYAD
|
-439.8 | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
-69.03 | - | -7.31 % | $ 87 M | USA |
 |
Celldex Therapeutics
CLDX
|
-54.51 | $ 29.81 | -0.42 % | $ 1.98 B | USA |
 |
Generation Bio Co.
GBIO
|
-165.18 | - | - | $ 344 M | USA |
 |
IMV
IMV
|
-79.29 | - | - | $ 13.1 M | Canada |
 |
Akero Therapeutics
AKRO
|
-38.05 | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-37.16 | - | 0.23 % | $ 488 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3412.47 | - | - | $ 7.46 M | Israel |
|
Enlivex Therapeutics Ltd.
ENLV
|
-0.65 | $ 0.75 | -4.78 % | $ 34.3 M | Israel |
 |
Esperion Therapeutics
ESPR
|
-19.96 | $ 3.13 | - | $ 651 M | USA |
 |
Eton Pharmaceuticals
ETON
|
-3.23 | $ 28.73 | -0.59 % | $ 773 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
-123.17 | - | -4.36 % | $ 27 M | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
-187.83 | - | - | $ 384 M | Britain |
 |
Gracell Biotechnologies
GRCL
|
-45.4 | - | - | $ 3.37 B | China |
|
Forte Biosciences
FBRX
|
-115.85 | $ 16.17 | -3.15 % | $ 209 M | USA |
 |
Anika Therapeutics
ANIK
|
-7.7 | $ 14.74 | -0.37 % | $ 211 M | USA |
 |
Advaxis
ADXS
|
429.74 | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-76.42 | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
-29.3 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-51.5 | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
-60.13 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-80.33 | - | 1.93 % | $ 17.4 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-146.69 | $ 3.16 | 0.01 % | $ 5.2 M | Israel |
 |
Aptose Biosciences
APTO
|
-46.69 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-163.42 | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
-70.32 | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
-58.56 | - | 4.14 % | $ 49.1 M | USA |